AstraZeneca Unloads Four NDAs to ANI Pharmaceuticals in $46.5M Deal Post author:Sam Post published:December 28, 2017 Post category:BioPharma ANI Phamaceuticals funded the acquisitions through a combination of cash and debt. Source: BioSpace You Might Also Like Late-Stage Life Sciences Investment Firm, Aisling Capital, Closes $280M Fund November 1, 2017 J&J Bows Out of Race for Pfizer's $20B Consumer Health Biz January 25, 2018 Lamellar Biomedical Ltd Raises ??5.75 Million In Series C Fund Raising Led By May 7, 2017
